



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,454	06/20/2005	Yongfeng Wang	16188.0001U1	8104
23850 7590 10/06/2008 Ballard Spahr Andrews & Ingersoll, LLP SUITE 1000 999 PEACHTREE STREET ATLANTA, GA 30309-3915				
EXAMINER				
YOUNG, MICAH PAUL				
ART UNIT		PAPER NUMBER		
1618				
MAIL DATE		DELIVERY MODE		
10/06/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/529,454

Applicant(s)

WANG ET AL.

Examiner

MICAH-PAUL YOUNG

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-14 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 March 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SE/US)
Paper No(s)/Mail Date 6/20/05
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 6/20/05 was filed on the mailing date of the Specification on 6/20/05. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 2 are rejected under 35 U.S.C. 102(b) as being anticipated by Ragab (WO 00/57867 hereafter '867). The claims are drawn to a controlled release formulation comprising temozolomide.

The '867 patent teaches a sustained release temozolomide formulation comprising at least 3.3% (page 4). Regarding the "implantable" limitation it is the position of the Examiner that the disclosures of the prior art anticipates the instant claims since the limitation is merely a future intended use. Where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation. See also *Rowe v. Dror*, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-9 rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Ragab (WO 00/57867 hereafter '867) in view of Gopferick (USPN 6,086,908 hereafter '908). The claims are drawn to a controlled release formulation comprising a polyanhydride combination. The claims also recite a method of making the formulation.

As discussed above the '867 patent discloses a controlled release formulation comprising temozolomide and controlled release polymers. The reference is silent to the specific polyanhydride of the instant claims, however these polymers are well known in the controlled release arts. This can be seen in the '908 patent.

The '908 patent discloses an implant tablet for sustained release comprising 3, 4-bis (p-carboxyphenoxy) propane (CPP) and sebacic acid in a ratio of 20:80 (examples). The reference discloses a method of making the tablets comprising dissolving the polymers in an appropriate

solvent, dispersing a drug into the dissolved polymer, forming particles of the polymer/drug combination by evaporating the solvent, and compressing these particles into a tablet (col. 2, lin. 55-col. 3, lin. 20). The reference silent to spray-drying the dissolved polymer formulation in order to arrive at the microparticles, however the process of the '908 patent result sin the same controlled release implantable tablet as the instant claims. Particles of a dispersed active agent and polymer are formed, and then further compressed into a tablet. Since the result of the process steps is the same formulation it is the position of the Examiner that the disclosures of the prior art obviate the instant claims.

With these things in mind it would have been obvious to combine the cancer agents of the '867 patent into the formulation of the '908 patent in order to provide a stable long term implantable device. One of ordinary skill in the art would have been motivated to combine the teachings and suggestions of the art as such with an expected result of a stable drug formulation useful in providing sustained cancer treating relief.

Claims 7 and 10-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Ragab (WO 00/57867 hereafter '867) in view of Gopferick (USPN 6,086,908 hereafter '908) and Sjoblom (USPN 6,753,014 hereafter '014). The claims are drawn to a process for making a controlled release tablet comprising dispersing the drug in a dissolve polymer, forming particles from this mixture by ultrasonic emulsifying, forming microspheres and tableting the resulting spheres.

As discussed above the '867 patent and the '908 patent provide a method of making controlled release tablets comprising temozolomide and CPP-SA-20:80 polymers by dispersing the drug into the polymer, forming particles and compressing the particles into a tablet. The

combination is silent to the formation of particles via an emulsifying process, or the specific solvent used to form the polymer solution. The formation of microparticles from an emulsion is well known in the art as well as an appropriate solvent for CPP-SA 20:80, these elements are taught by the '014 patent.

The '014 patent discloses a method of making stable sustained release tablet comprising forming particles of dispersed drug compounds and polymers, and compressing the particles into stable tablets (abstract). First solutions of polymeric materials are formed by dissolving the mixing in a solvent such as methyl chloride (claim 14); next active agents are combined with the solution before it is emulsified through an ultrasonic nozzle (col. 5, lin. 19-35). The emulsion can be mixed with other polymers before the solvent is removed and microspheres are formed (col. 5, lin. 50-col. 6, lin. 30). The microspheres compressed into a tablet (col. 7, lin. 25-30). It would have been obvious to use the method of the '014 patent since many of the polymeric materials are similar to those of the '908 patent.

With these things in mind it would have been obvious to combine the teachings and suggestions of the prior art with an expected result of the stable controlled release tablet. The artisan would have been motivated to use the method of the '014 patent in order to protect the anti cancer agents of the '867 patent from excessive heat. One of ordinary skill in the art would have been motivated to combine these disclosures with an expected result of a stable long term ant-cancer formulation.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH-PAUL YOUNG whose telephone number is (571)272-

0608. The examiner can normally be reached on Monday-Friday 7:00-4:30; every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

/MICAH-PAUL YOUNG/
Examiner, Art Unit 1618